Prognostic Value of Some Biochemical Markers in Breast Cancer
1 other identifier
observational
90
1 country
1
Brief Summary
breast cancer is the most common type of cancer in women and first cause of cancer death among them. in Egypt it constitutes 33% of female cancer cases and more than22000 new cases diagnosed each year. there are many prognostic factors for breast cancer as Tumer size, axillary lymph node status, hormonal receptor status, and tumer markers as Ca15-3 and interferon gamma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2023
CompletedFirst Posted
Study publicly available on registry
January 26, 2023
CompletedStudy Start
First participant enrolled
February 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2023
CompletedJanuary 26, 2023
January 1, 2023
10 months
January 17, 2023
January 17, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
serum level of Ca15-3
Tumer marker
6 months
serum level of interferon gamma
Tumer marker
6 months
Study Arms (2)
metastatic breast cancer
non metastatic breast cancer
Interventions
ELIZA for Ca15-3 and interferon gamma
Eligibility Criteria
female patients with breast cancer
You may qualify if:
- female patients aged more than or equal 18 year diagnosed with breast cancer
- metastatic and non-metastatic cancer premenopausal and postmenopausal female positive and negative hormonal receptors and HER2 receptor taking any systemic treatment taking radiotherapy or not
You may not qualify if:
- female patients less than 18 years patients having comorbid disease. patients with double malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University Hospital
Sohag, Egypt
Related Publications (4)
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PMID: 33538338BACKGROUNDUygur MM, Gumus M. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treat Res Commun. 2021;28:100402. doi: 10.1016/j.ctarc.2021.100402. Epub 2021 May 24.
PMID: 34082362BACKGROUNDJorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res. 2020 Sep 29;8:49. doi: 10.1186/s40364-020-00228-x. eCollection 2020.
PMID: 33005420BACKGROUNDMendoza JL, Escalante NK, Jude KM, Sotolongo Bellon J, Su L, Horton TM, Tsutsumi N, Berardinelli SJ, Haltiwanger RS, Piehler J, Engleman EG, Garcia KC. Structure of the IFNgamma receptor complex guides design of biased agonists. Nature. 2019 Mar;567(7746):56-60. doi: 10.1038/s41586-019-0988-7. Epub 2019 Feb 27.
PMID: 30814731BACKGROUND
Central Study Contacts
muhammed a abd el moety, professor
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- demonestrator at medical biochemistry
Study Record Dates
First Submitted
January 17, 2023
First Posted
January 26, 2023
Study Start
February 1, 2023
Primary Completion
December 1, 2023
Study Completion
December 1, 2023
Last Updated
January 26, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will share